We think the cloud holds substantial--and underestimated--opportunity for some of these companies.
The semiconductor space is a constant battle against commoditization.
The global COVID-19 vaccine market is currently dominated by mRNA firms, but competitors are gaining strength.
Limited vaccine supply in other countries could make global immunity tougher to achieve, though.
Here's how regulation can dictate their growth and valuation.
But more-affordable homes will be needed to realize millennials' ownership potential.
We've increased our U.S. GDP growth forecast.
We think the market misunderstands the ramifications of e-commerce.
A look at the automakers and suppliers that are best positioned to benefit from the industry's recovery.
Competition presents headwinds to players in the travel market, however.
It's been left behind in the runup in energy prices, and here's why.
But more dots move toward a rate hike--or hikes--in 2022 or 2023.
We think Marriott and Hilton are the best positioned.
Productive capacity, not stimulus, is what drives the economy’s long-term potential GDP.
Despite stubbornly high unemployment, we have reason to believe fiscal stimulus has helped household finances hold up across all income levels.
Lockdowns and next-generation consoles are supercharging growth.
The U.S. economic recovery paused at the end of 2020, but it will soon be ready for liftoff.
We see the best values in high-quality gas utilities.
If liquid biopsy lives up to its potential, a paradigm shift in cancer detection is possible.
High yields indicate opportunity as the probability of cuts is low.
We see strong growth and reduced cyclicality for the industry.
The sector's expensive overall, and some valuations are downright alarming.
However, the biopharma industry's ability to adapt and innovate to treat disease reinforces our moat ratings.
We expect quickly declining sales potential after that, however.
Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.
We think the effects are likely to be minimal for the companies we cover.
We think not, and the market's misperception results in an attractive share price for NiSource.
We think the insurers could be most influenced by potential reforms.
The impact of the pandemic on electronic payment providers has been far from even.
With consumers flocking online during COVID-19, demand for digital ads should be strong in 2021 and beyond.
Small tickets and low-income customers are safeguards.
Robots are becoming more central to the orthopedic field, but widespread adoption still faces considerable hurdles.
But the disruption caused by COVID-19 has little effect on the device industry’s moats.
We don't foresee any impact on pharma companies' moats or valuations.
Utilities should benefit as the U.S. economy electrifies.
Stabilizing pricing and improved efficiencies should lead to steady gains and needed debt repayments for the generic drugmakers.
Here's a playbook for exploration and production companies to restore investor confidence.
But plenty of upside remains.
Neither the U.S. election outcome nor the coronavirus third wave will derail it.
Macroeconomic impact will likely be muted, and the boost in taxes and spending won't be unprecedented.
In the event of a Biden win, aftertax earnings could take a hit from higher corporate taxes.
Weaning America off fossil fuels will take decades, even if Democrats sweep Congress in November.
Companies with U.S. exposure are better positioned to benefit from easing prohibition.
Clean energy plans could be long-term growth opportunities.
Although the pandemic has proved the viability of remote work, we think offices are here to stay.
We don't think the market appreciates Caesars' and MGM's leading presence in domestic athletic gambling.
While we believe that most publicly traded restaurant companies will survive COVID-related disruptions, we still believe that the worst may be yet come for the broader industry.
Despite a difficult market, their advantages are intact.
We're still ambivalent about recent M&A, though.
Our moat ratings and undervalued view of the MCO and drug/biotech sectors are intact.